ATE373492T1 - Formulierung zur parenteralen applikation eines na-kanal-blockers - Google Patents

Formulierung zur parenteralen applikation eines na-kanal-blockers

Info

Publication number
ATE373492T1
ATE373492T1 AT03735445T AT03735445T ATE373492T1 AT E373492 T1 ATE373492 T1 AT E373492T1 AT 03735445 T AT03735445 T AT 03735445T AT 03735445 T AT03735445 T AT 03735445T AT E373492 T1 ATE373492 T1 AT E373492T1
Authority
AT
Austria
Prior art keywords
formulation
channel blocker
parenteral application
parenteral
application
Prior art date
Application number
AT03735445T
Other languages
German (de)
English (en)
Inventor
Bernd Kruss
Annerose Mauz
Karin Ruehr
Jean-Marie Stassen
Claus Veit
Klaus Wagner
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE373492T1 publication Critical patent/ATE373492T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03735445T 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers ATE373492T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Publications (1)

Publication Number Publication Date
ATE373492T1 true ATE373492T1 (de) 2007-10-15

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03735445T ATE373492T1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers

Country Status (12)

Country Link
EP (1) EP1511517B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005527615A (cg-RX-API-DMAC7.html)
AR (1) AR040134A1 (cg-RX-API-DMAC7.html)
AT (1) ATE373492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003237664A1 (cg-RX-API-DMAC7.html)
CA (1) CA2487150A1 (cg-RX-API-DMAC7.html)
DE (2) DE10223783A1 (cg-RX-API-DMAC7.html)
ES (1) ES2294295T3 (cg-RX-API-DMAC7.html)
PE (1) PE20040066A1 (cg-RX-API-DMAC7.html)
TW (1) TW200400029A (cg-RX-API-DMAC7.html)
UY (1) UY27823A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003099336A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6565880B2 (en) * 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Also Published As

Publication number Publication date
DE50308227D1 (de) 2007-10-31
DE10223783A1 (de) 2003-12-11
EP1511517A1 (de) 2005-03-09
ES2294295T3 (es) 2008-04-01
JP2005527615A (ja) 2005-09-15
AU2003237664A1 (en) 2003-12-12
EP1511517B1 (de) 2007-09-19
PE20040066A1 (es) 2004-03-22
WO2003099336A1 (de) 2003-12-04
AR040134A1 (es) 2005-03-16
CA2487150A1 (en) 2003-12-04
UY27823A1 (es) 2003-12-31
TW200400029A (en) 2004-01-01

Similar Documents

Publication Publication Date Title
DE50208649D1 (de) Verfahren zur bereitschaftshaltung eines kombikraftwerkes
IL187330A0 (en) A method of marking composition for oral administration
NO20043386L (no) Monteringsverktoy for bronnpakninger
EP1891296A4 (en) PACKAGING DEVICE WITH POSITIONABLE RING
DE50305969D1 (de) Verfahren zur herstellung eines kurzkanal-feldeffekttransistors
GB2401436B (en) A method for determining the composition of a fluid
ATA20532003A (de) Innenschalungsabschnitt zur errichtung eines bauwerksabschnitts
DE50303253D1 (de) Verfahren zur analyse der kanalimpulsantwort eines übertragungskanals
EP1595506A4 (en) DEVICE FOR FORMING AN EMBOLUS
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
DE60322943D1 (de) Indanverbindung enthaltende nematischflüssigkristalline zusammensetzung
IL178366A0 (en) Pharmaceutical compositions containing a calcium channel blocker and thiamine
EP1618894A4 (en) COMPOSITION FOR INJECTION
DE602004015009D1 (de) Verfahren zur Hestellung eines Tetraalkyloniumperfluoralkylsulfonats
ATE373492T1 (de) Formulierung zur parenteralen applikation eines na-kanal-blockers
ATE420734T1 (de) Düse zur bandbeschichtung
ATE538519T1 (de) Bauelement zur herstellung eines kabelkanals
ATE358167T1 (de) Selbstoxydierbare architektonische beschichtungszusammensetzungen
FR2877088B1 (fr) Methode de decoincement d'un pneumatique
DE60028096D1 (de) Kanaleingabe zur Auswahl eines Kanals
DE50201242D1 (de) Verfahren zur schätzung eines codecparameters
ITBO20020303A1 (it) Nuovi otturatori per valvole a farfalla
DE502004001168D1 (de) Führungsrinne
DE502004004245D1 (de) Einrichtung zur einstellung eines veränderlichen durchflussq uerschnitts
AU2003216564A1 (en) Device for guiding of sliding constructions

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee